Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Bausch & Lomb Wins Battle For Ista
by Lisa M. Jarvis
April 2, 2012
| A version of this story appeared in
Volume 90, Issue 14
Bausch & Lomb plans to expand its eye drug pipeline through the $500 million acquisition of Irvine, Calif.-based Ista Pharmaceuticals. Bausch & Lomb is stepping in after a failed hostile takeover of Ista by Valeant Pharmaceuticals. Last October, Valeant offered roughly $314 million for the eye-care company; it raised the offer in January but later abandoned it after failing to come to an agreement with Ista management. Bausch & Lomb says it already has a good working relationship with Ista because for years it has manufactured most of Ista’s U.S. product line.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter